Meet our 2024 Accelerator Cohort: Aspedan
In the first of this new series introducing our 2024 Advanced Wellbeing Accelerator cohort, we chat to Madison Rose, CEO and founder of Aspedan, who develop incentivised, personalised, and medically validated health plans.
Hi, Madison! Can you talk us through how you developed your business idea and what stage are you at now?
The idea for Aspedan arose based on a vision to help create a world where every person is able to maximise their healthy lifespan and reduce the incidence of chronic yet preventable diseases. We used our extensive experience of using what was currently on the market, recognising the frustrations and shortfalls, and then fixing them and making them better in our own product.
Aspedan’s novel and innovative platform autonomously delivers personalised, incentivised and medically validated health plans. We have built our patent-pending IP, the Aspedan Bioanalytics Engine, and the Aspedan app. We have conducted app engagement trials, and are now seeking to get our app and products onto the market, whilst we build our exciting new feature which will specifically help people with high blood pressure (also known as hypertension) to reduce their blood pressure to healthy levels.
What healthcare challenge do you address?
We are currently looking to address the broad healthcare challenge of endemic population ill-health and unhealthy ageing. Far too many people in the UK and globally are suffering from chronic yet preventable diseases, and people spend far too long in their later years of life in poor health – for example, conditions like heart disease, of which 80% of cases can be prevented with consistent healthy lifestyle choices.
What do you see as the main UK and international opportunities for your business?
In the UK, we would love to start working with the NHS. There are also lots of exciting opportunities for us to enter the private health sector. But we are also focussing on working directly with people to become their digital twin, designed to support them every single day to improve their health and live healthier, for longer.
Digital health as a market is incredibly exciting both in the UK and internationally at the moment – we are passionate about working anywhere where we have the potential to genuinely help improve people’s health and their lives. We’d be particularly keen to start working in emerging digital health markets, including the US, India, and Singapore.
What’s next? What are you currently focused on achieving?
Our current focus is on a few big things. Number one is to get our products, including our app, Bluetooth blood pressure monitors and Bluetooth scales, on the market. Number two is running more trials, particularly with the NHS. Three, securing further funding to expedite our business growth. Four, growing our team and bringing new skill sets into this highly exiting stage in our journey. And five is further product development – alongside our hypertension feature, we are building in additional features which will cater to other specific diseases and health conditions. We are also developing our incredibly exciting HealthiMe, which we can tell people more about it due course!
Thanks Madison, we’re excited to have Aspedan on the 2024 accelerator programme. Join us next Monday as we introduce more of the 2024 cohort.